Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 18/20 | 0.73 |
| ▸ | SOAT1 | P35610 | 12/20 | 0.73 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.44 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13747427 | 0.91 | DGAT1 (0.59) | DGAT1SOAT1DGAT2MAPTNPC1 | |
| SCHEMBL14336182 | 0.91 | DGAT1 (0.59) | DGAT1SOAT1DGAT2MAPTNPC1 | |
| SCHEMBL1399583 | 0.89 | DGAT1 (0.81) | DGAT1SOAT1DGAT2MAPTNPC1 | |
| SCHEMBL1399582 | 0.89 | DGAT1 (0.81) | DGAT1SOAT1DGAT2MAPTNPC1 | |
| SCHEMBL14342677 | 0.88 | DGAT1 (0.81) | DGAT1SOAT1DGAT2ACAT1 | |
| SCHEMBL2244897 | 0.88 | DGAT1 (0.81) | DGAT1SOAT1DGAT2ACAT1 | |
| SCHEMBL2249148 | 0.88 | DGAT1 (0.81) | DGAT1SOAT1DGAT2ACAT1 | |
| SCHEMBL2244904 | 0.88 | DGAT1 (0.81) | DGAT1SOAT1DGAT2ACAT1 | |
| SCHEMBL1399692 | 0.87 | DGAT1 (0.77) | DGAT1SOAT1DGAT2ACAT1 | |
| SCHEMBL3411044 | 0.85 | DGAT1 (1.00) | DGAT1SOAT1DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035417-B1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
| EP-2035417-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007141517-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | DGAT1, ACAT1, DGAT2 | DGAT1 1/4885SOAT1 5/4885DGAT2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.